Mitoxantrone in first-relapse paediatric ALL: The ALL R3 trial

The Lancet

Volumn 376, Issue 9757, 2010, Pages 1968-1970

  Schrappe, Martin ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IDARUBICIN; MITOXANTRONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HEMATOLOGIC DISEASE; HUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 78650172205     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62194-0     Document Type: Letter

References (13)

1. M Schrappe, J Nachman, S Hunger Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000) Leukemia 24 2010 253 254
2. CH Pui, WE Evans Treatment of acute lymphoblastic leukemia N Engl J Med 354 2006 166 178
3. A Moricke, A Reiter, M Zimmermann for the German-Austrian-Swiss ALL-BFM Study Group Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 Blood 111 2008 4477 4489
4. SE Sallan, RD Gelber, V Kimball, M Donnelly, HJ Cohen More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials Haematol Blood Transfus 33 1990 459 466
5. KC Oeffinger, AC Mertens, CA Sklar Chronic health conditions in adult survivors of childhood cancer N Engl J Med 355 2006 1572 1582
6. G Tallen, R Ratei, G Mann Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90 J Clin Oncol 28 2010 2339 2347
7. PS Gaynon Childhood acute lymphoblastic leukaemia and relapse Br J Haematol 131 2005 579 587
8. P Bader, H Kreyenberg, GH Henze Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group J Clin Oncol 27 2009 377 384
9. C Parker, R Waters, C Leighton Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial Lancet 2010 10.1016/S0140-6736(10)62002-8 published online Dec 4.
10. A Reiter, M Schrappe, W-D Ludwig Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86 Blood 84 1994 3122 3133
11. JJM van Dongen, T Seriu, ER Panzer-Grümayer Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 352 1998 1731 1738 (Pubitemid 28534955)
12. VH van der Velden, A Hochhaus, G Cazzaniga, T Szczepanski, J Gabert, JJ van Dongen Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects Leukemia 17 2003 1013 1034
13. M Bruggemann, A Schrauder, T Raff Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 Leukemia 24 2010 521 535